Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

GCM Medical Group PSC

Neither a doctor nor a teaching hospital

Research payments

$17,242,493

1,382 payments

Through program year 2025, GCM Medical Group PSC is reported as receiving $17,242,493 in research payments, across 1,382 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,329,918 331
2024 Research $2,820,513 300
2023 Research $2,056,623 210
2022 Research $2,335,592 277
2021 Research $2,303,867 163
2020 Research $1,845,427 45
2019 Research $2,550,553 56

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly Export S.A. Puerto Rico Branch $10,818,810 119 payments
  2. AbbVie, Inc. $2,862,580 738 payments
  3. Eli Lilly and Company $1,413,903 246 payments
  4. Janssen Research & Development, LLC $451,547 59 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $448,581 78 payments
  6. E.R. Squibb & Sons, L.L.C. $372,373 13 payments
  7. Sanofi US Services Inc. $316,158 76 payments
  8. Amgen Inc. $155,898 9 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $148,197 3 payments
  10. Vertex Pharmaceuticals Incorporated $113,096 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With Or Without Sglt2 Inhibitor (Transcend-T2d-2) $1,002,661 4 payments
  2. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $861,341 20 payments
  3. A Randomized, Phase 3, Open-Label Trial Comparing the Effect of Ly3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes $722,929 6 payments
  4. Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity Or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-2) $717,945 12 payments
  5. A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight With Weight Related Comorbidities (Attain-1) $692,904 4 payments
  6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata $580,121 10 payments
  7. A Phase 2, Parallel, Comparator Controlled Trial to Evaluate the Safety and Efficacy of Ly3209590 in Insulin Naive Patients With Type 2 Diabetes Mellitus $498,930 9 payments
  8. A Study of Ly3209590 in Participants With Type 2 Diabetes Mellitus $454,164 4 payments
  9. Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent $451,547 59 payments
  10. A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Ly3074828 in Patients With Moderate-To-Severe Plaque Psoriasis Oasis-3 $446,258 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record